Origin and properties of soluble CD21 (CR2) in human blood

Clinical and Experimental Immunology

Volumn 113, Issue 3, 1998, Pages 360-366

  Ling, N R ^a   Hardie, D L ^a   Johnson, G D ^a   Maclennan, I C M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Blood; CD21; Soluble CR2

Indexed keywords

COMPLEMENT COMPONENT C3D RECEPTOR;

ANTIGEN DETECTION; ARTICLE; B LYMPHOBLAST; BLOOD; BURKITT LYMPHOMA; DNA TRANSFECTION; HUMAN; HUMAN CELL; KERATINOCYTE; LEUKEMIA CELL LINE; LYMPHOBLASTOID CELL LINE; PRIORITY JOURNAL; RAJI CELL; TONSIL;

ANIMALS; DENDRITIC CELLS; HUMANS; MICE; RECEPTORS, COMPLEMENT 3D; TUMOR CELLS, CULTURED;

EID: 0031658929     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00668.x     Document Type: Article

References (27)

1. Timens W, Boes A, Poppema S. Human marginal zone B cells are not an activated B cell subset; strong expression of CD21 as a putative mediator for rapid B cell activation. Eur J Immunol 1989; 19:2163-6.
2. Dorken B, Moller P, Pezzutto A, Schwartz-Albiez R, Moldenhauer G. B cell antigens; CD21. In: Knapp W, ed. Leucocyte typing IV. Oxford: Oxford University Press, 1989:58-60.
3. Ling NR, MacLennan ICM, Mason DY. B cell and plasma cell antigens. In: McMichael AJ, ed. Leucocyte typing III. Oxford: Oxford University Press, 1987:302-35.
4. Lowell CA, Klickstein LB, Carter RH, Mitchell JA, Fearon DT, Ahearn JM. Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J Exp Med 1989; 170:1931-46.
5. Barclay AN, Brown AH, Law SKA, McKnight AJ, Tomlinson MG, van der Merwe PA. The leucocyte antigen facts book, 2nd edn. New York: Academic Press, 1997:183-5.
6. Weis JJ, Richards SA, Smith JA, Fearon DT. Purification of the B lymphocyte receptor for the C3d fragment of complement and the Epstein-Barr virus by monoclonal antibody affinity chromatography and assessment of its functional capacities. J Immunol Methods 1986; 92:79-88.
7. Lowe J, Brown B, Hardie D, Richardson P, Ling NR. Soluble forms of CD21 and CD23 antigens in the serum in B cell chronic lymphocytic leukaemia. Immunol Letters 1989; 20:103-10.
8. Ling NR, Brown B. Properties of soluble CR2 in human serum. Immunobiol 1992; 185:403-14.
9. Ling NR, Hansell T, Richardson PR, Brown B. Cellular origins of serum complement receptor type 2 in normal individuals and in patients with hypogammaglobulinaemia. Clin Exp Immunol 1991; 54:16-22.
10. Fischer E, Delibrias C, Kazatchkine MD. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human blood T lymphocytes. J Immunol 1991; 146:865-9.
11. Tsoukas CD, Lambris JD. Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies. Eur J Immunol 1988; 18:1299.
12. Gasque P, Chan P, Mauger C, Schouft M-T, Singhrao S, Dierich MP, Morgan BP, Fontaine M. Identification and characterisation of complement C3 receptors on human astrocytes. J Immunol 1996; 156:2247-55.
13. Sinha SK, Todd SC, Hedrick JA, Speiser CL, Lambris JD, Tsoukas CD. Characterisation of the EBV/C3d receptor on the human Jurkat T cell line: evidence for a novel transcript. J Immunol 1993; 150:5311.
14. MacLennan ICM. Germinal centers. Ann Rev Immunol 1994; 12:117-39.
15. Toothaker LE, Henjes AJ, Weis JJ. Variability of CR2 gene products due to alternative exon usage and different CR2 alleles. J Immunol 1989; 142:3668-75.
16. Liu Y-J, Xu J, de Bouteiller O et al. Follicular dendritic cells specifically express the long CR2/CD21 isoform. J Exp Med 1997; 185:165-70.
17. Naiem M, Gerdes J, Abdulaziz Z, Stein H, Mason DY. Production of a monoclonal antibody reactive with human dendritic reticulum cells and its use in the immunohistological analysis of lymphoid tissue. J Clin Pathol 1983; 36:167-75.
18. Johnson GD, Hardie DL, Ling NR, MacLennan ICM. Human follicular dendritic cells (FDC): a study with monoclonal antibodies. Clin Exp Immunol 1986; 64:205-13.
19. Ling NR, Brown B, Hardie D. Synergy test for recognition of epitopes on soluble proteins; its application in the study of CD21 and CD23 antigens and their respective antibodies. J Immunol Methods 1994; 173:11-17.
20. Ling NR, Brown B, Hardie D. Synergy test for measuring epitope recognition by CD21 mAbs. Leucocyte Typing V 1995; 1:521-3.
21. Aubry JP, Pochon S, Gauchet JF, Nueda Marin A, Holers VM, Graber P, Siegfried C, Bonnefoy JF. CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharide on CD21. J Immunol 1994; 152:5806.
22. Schendinger MG, Spruth M, Schoch J, Dierich MP, Prodinger WM. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells. J Immunol 1997; 158:5455-63.
23. Fremaux-Bacchi V, Fischer E, Bonnefoy JY, Kazatchkine MD. Soluble trimeric CD23 and C3 fragments are associated with CD21 in normal human serum. Immunol Letters 1997; 56:111.
24. Reynes M, Aubert JP, Cohen JHM, Audouin J, Tricottet V, Diebold J, Kazatchkine MD. Human follicular dendritic cells express CR1, CR2 and CR3 complement receptor antigens. J Immunol 1985; 135:2687-94.
25. Ling NR, Stevenson SK, Brown B. Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia. Clin Exp Immunol 1991; 86:360-6.
26. Nemerow G, Mullin JJ, Dickson FW, Cooper NR. Soluble recombinant CR2 inhibits Epstein-Barr virus infection. J Virol 1990; 64:1348-52.
27. Hebell T, Ahearn JM, Fearon DT. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 1991; 254:102-5.